TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy
Brief Summary: The goal of REMEDIUM project is to develop personalized stem cell therapy for patients with chronic heart failure due to dilated cardiomyopathy (DCM). The main focus of the project is (1) on repetitive administration of cell therapy that would allow for long-lasting improvements in heart function and outcome in this patient population. In parallel, the investigators aim to (2) develop a standardized patient-specific stem cell product that could be cryopreserved and stored in a stem cell bank for prolonged time periods, and used for therapeutic application when clinically indicated. By using a unique multimodality imaging platform, the goal of this project is also to (3) define standardized clinical criteria that would serve as a guideline for evaluation of the effects of stem cell therapy in future clinical trials and everyday clinical settings. Finally, to improve the clinical implementation of cell therapy,the investigators aim to (4) develop a stem cell delivery technique that could be used to treat both left and right and ventricular failure and could be implemented in a standardized fashion designed for a widespread clinical use.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Stem cell therapy | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Stem cell therapy | Intervention Type: BIOLOGICAL; Name: Stem cell therapy; Assigned to Arm(s): Group A, Group B
B: Arm Label: SC Group; Type: EXPERIMENTAL; Interventions: Biological: CD34+ autologous stem cell transplantation, Drug: Bone Marrow Stimulation, Biological: SC therapy | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: CD34+ autologous stem cell transplantation; Assigned to Arm(s): SC Group | Intervention Type: DRUG; Name: Bone Marrow Stimulation; Assigned to Arm(s): SC Group | Intervention Type: BIOLOGICAL; Name: SC therapy; Assigned to Arm(s): SC Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous human mesenchymal cells (hMSCs) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous human bone marrow cells (hBMCs) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Autologous human mesenchymal cells (hMSCs); Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Autologous human bone marrow cells (hBMCs); Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Assessment of a New Physiotherapy Protocol for Gait Recovery After Stroke Based on Clinical and Functional Criteria
Brief Summary: The purpose of this study was to identify and evaluate the effect of a new protocol of physiotherapy to retrain walking ability after stroke in subjects older than fifty-five. This protocol was composed of specific, clearly defined and reproducible techniques, based on clinical and functional criteria.


Options:
A: Arm Label: VRT; Type: EXPERIMENTAL; Interventions: Other: virtual reality training | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: control | Intervention Type: OTHER; Name: virtual reality training; Assigned to Arm(s): VRT | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control
B: Arm Label: Start with Visual + Force; Type: EXPERIMENTAL; Interventions: Other: Visual + Force Feedback, Other: Visual + Force + Game Scores Feedback | Arm Label: Start with Visual + Force + Game Scores; Type: EXPERIMENTAL; Interventions: Other: Visual + Force Feedback, Other: Visual + Force + Game Scores Feedback | Intervention Type: OTHER; Name: Visual + Force Feedback; Assigned to Arm(s): Start with Visual + Force, Start with Visual + Force + Game Scores | Intervention Type: OTHER; Name: Visual + Force + Game Scores Feedback; Assigned to Arm(s): Start with Visual + Force, Start with Visual + Force + Game Scores
C: Arm Label: Trunk training; Type: EXPERIMENTAL; Interventions: Other: Trunk training | Arm Label: Cognitive exercises; Type: SHAM_COMPARATOR; Interventions: Other: Cognitive exercises | Intervention Type: OTHER; Name: Trunk training; Assigned to Arm(s): Trunk training | Intervention Type: OTHER; Name: Cognitive exercises; Assigned to Arm(s): Cognitive exercises
D: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional physiotherapy | Arm Label: Target group; Type: EXPERIMENTAL; Interventions: Other: Conventional physiotherapy, Other: Techniques based on patients' functional level were added. | Intervention Type: OTHER; Name: Conventional physiotherapy; Assigned to Arm(s): Control group, Target group | Intervention Type: OTHER; Name: Techniques based on patients' functional level were added.; Assigned to Arm(s): Target group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study aimed to compare dobutamine stress echocardiography (DES) with computed tomography coronary angiography (CTCA) in patients with undergoing intermediate to high risk noncardiac surgery.


Options:
A: Arm Label: Coronary Stent; Type: N/A; Interventions: N/A
B: Arm Label: Fludarabine; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine | Arm Label: watch & wait; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Fludarabine
C: Arm Label: patients with hip fracture; Type: N/A; Interventions: Other: observation | Intervention Type: OTHER; Name: observation; Assigned to Arm(s): patients with hip fracture
D: Arm Label: DSE; Type: N/A; Interventions: N/A | Arm Label: CTCA; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder
Brief Summary: This study compares the efficacy of embedding avatars into an online self-management program that teaches OAB behavioral therapy on OAB-related quality of life, symptoms, self-efficacy, and adherence versus the same program without avatars


Options:
A: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2
C: Arm Label: Avatar group; Type: EXPERIMENTAL; Interventions: Other: Avatar group | Arm Label: No Avatar group; Type: ACTIVE_COMPARATOR; Interventions: Other: No Avatar group | Intervention Type: OTHER; Name: Avatar group; Assigned to Arm(s): Avatar group | Intervention Type: OTHER; Name: No Avatar group; Assigned to Arm(s): No Avatar group
D: Arm Label: Health education intervention (HEI); Type: EXPERIMENTAL; Interventions: Behavioral: Health education intervention (HEI) | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health education intervention (HEI); Assigned to Arm(s): Health education intervention (HEI)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility and Accuracy of a Novel Xpert Cartridge for Rapid Molecular Detection of Drug Resistant Mycobacterium Tuberculosis in Sputum
Brief Summary: Consenting adults will be interviewed for demographic and medical information, and then will be asked to provide two expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis.


Options:
A: Arm Label: TB case detection Group; Type: N/A; Interventions: Device: Cepheid Gene Xpert MTB/XDR | Arm Label: RIF-resistance MTB Group; Type: N/A; Interventions: Device: Cepheid Gene Xpert MTB/XDR | Intervention Type: DEVICE; Name: Cepheid Gene Xpert MTB/XDR; Assigned to Arm(s): RIF-resistance MTB Group, TB case detection Group
B: Arm Label: PLHIV Centralised Xpert Ultra; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert Ultra; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert Ultra | Arm Label: PLHIV Centralised Xpert VL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert VL; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert VL | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert Ultra; Assigned to Arm(s): PLHIV Point of Care Xpert Ultra | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert VL; Assigned to Arm(s): PLHIV Point of Care Xpert VL
C: Arm Label: Case detection group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Arm Label: Drug resistance risk group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Intervention Type: DEVICE; Name: Investigational Xpert DST test; Assigned to Arm(s): Case detection group, Drug resistance risk group
D: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility and Accuracy of a Novel Xpert Cartridge for Rapid Molecular Detection of Drug Resistant Mycobacterium Tuberculosis in Sputum
Brief Summary: Consenting adults will be interviewed for demographic and medical information, and then will be asked to provide two expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis.


Options:
A: Arm Label: Smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear | Arm Label: GeneXpert; Type: EXPERIMENTAL; Interventions: Other: Xpert | Intervention Type: OTHER; Name: Xpert; Assigned to Arm(s): GeneXpert | Intervention Type: OTHER; Name: Smear; Assigned to Arm(s): Smear
B: Arm Label: Case detection group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Arm Label: Drug resistance risk group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Intervention Type: DEVICE; Name: Investigational Xpert DST test; Assigned to Arm(s): Case detection group, Drug resistance risk group
C: Arm Label: Antiretroviral therapy, tuberculosis; Type: N/A; Interventions: N/A
D: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Influence of Once-daily Versus Twice-daily Immunosuppressive Regimen on Drug Compliance in Patients After Renal Transplantation
Brief Summary: The main objective of this study was to compare the drug compliance in patients after renal transplantation under once or twice-daily tacrolimus-based immunosuppressive regimen.

The rationale for this study is to access the influence of once-daily prolonged-release tacrolimus versus standard twice-daily tacrolimus on drug compliance in renal transplantation recipients base on the assumption that once-daily dosing regimen may help to improve drug compliance.


Options:
A: Arm Label: ICT based monitoring group; Type: EXPERIMENTAL; Interventions: Device: Feedback using ICT based monitoring system | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Feedback using ICT based monitoring system; Assigned to Arm(s): ICT based monitoring group
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: mHealth Intervention | Intervention Type: OTHER; Name: mHealth Intervention; Assigned to Arm(s): mHealth Intervention
C: Arm Label: Advagraf; Type: EXPERIMENTAL; Interventions: Drug: Advagraf | Arm Label: Prograf; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prograf | Intervention Type: DRUG; Name: Advagraf; Assigned to Arm(s): Advagraf | Intervention Type: DRUG; Name: Prograf; Assigned to Arm(s): Prograf
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: TAKE IT Strategy | Intervention Type: BEHAVIORAL; Name: TAKE IT Strategy; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children
Brief Summary: Randomized, double-blind, placebo controlled trial of a combined intervention of zinc, albendazole, and multiple micronutrients in improving environmental enteropathy in Malawian children.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole), Drug: Anti-Giardia treatment only (secnidazole or albendazole), Drug: Control group (placebo) | Intervention Type: DRUG; Name: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Anti-Giardia treatment only (secnidazole or albendazole); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Control group (placebo); Assigned to Arm(s): 1
B: Arm Label: Multiple Intervention Arm; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Dietary Supplement: Zinc, Dietary Supplement: Multiple Micronutrient Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient Supplement; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Package of interventions; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lipid Nutrient Supplement, Drug: Sulfadoxine-pyrimethamine, Drug: Albendazole, Drug: Zinc, Other: Insecticide-treated bednet | Intervention Type: DIETARY_SUPPLEMENT; Name: Lipid Nutrient Supplement; Assigned to Arm(s): Package of interventions | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine; Assigned to Arm(s): Package of interventions | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Package of interventions | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Package of interventions | Intervention Type: OTHER; Name: Insecticide-treated bednet; Assigned to Arm(s): Package of interventions
D: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hybrid Approach to Mirror Therapy and Transcranial Direct Current Stimulation for Stroke Recovery: A Follow up Study on Brain Reorganization, Motor Performance of Upper Extremity, Daily Function, and Activity Participation
Brief Summary: We hypothesize that (1) the hybrid therapy will induce greater improvements on some health-related outcomes compared to other therapies; (2) such benefits will retain at 6-month follow-up; (3) better motor control and brain reorganization will be found in the hybrid therapy than the other therapies; (4) correlations will be found between brain activity and movement kinematics/health-related outcomes.


Options:
A: Arm Label: Mirror therapy with tDCS; Type: EXPERIMENTAL; Interventions: Behavioral: Mirror Therapy with tDCS | Arm Label: Mirror Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mirror Therapy | Arm Label: Control Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Intervention | Arm Label: Mirror Therapy with sham-tDCS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mirror Therapy with sham-tDCS | Intervention Type: BEHAVIORAL; Name: Mirror Therapy with tDCS; Assigned to Arm(s): Mirror therapy with tDCS | Intervention Type: BEHAVIORAL; Name: Mirror Therapy with sham-tDCS; Assigned to Arm(s): Mirror Therapy with sham-tDCS | Intervention Type: BEHAVIORAL; Name: Mirror Therapy; Assigned to Arm(s): Mirror Therapy | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention
B: Arm Label: Vojta arm; Type: EXPERIMENTAL; Interventions: Other: Vojta therapy | Arm Label: conventional physiotherapy arm; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional physiotherapy | Intervention Type: OTHER; Name: Vojta therapy; Assigned to Arm(s): Vojta arm | Intervention Type: OTHER; Name: conventional physiotherapy; Assigned to Arm(s): conventional physiotherapy arm
C: Arm Label: subcortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: cortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): cortical, subcortical
D: Arm Label: early mobilization; Type: EXPERIMENTAL; Interventions: Behavioral: early mobilization | Arm Label: early standard intervention; Type: OTHER; Interventions: Behavioral: early standard intervention | Intervention Type: BEHAVIORAL; Name: early mobilization; Assigned to Arm(s): early mobilization | Intervention Type: BEHAVIORAL; Name: early standard intervention; Assigned to Arm(s): early standard intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Assertive Community Treatment With Cognitive Behavioral Therapy and Social Skills Training for Schizophrenia.
Brief Summary: This project is an effectiveness trial comparing two psychosocial treatments for schizophrenia: Assertive Community Treatment (ACT) + Cognitive Behavioral Social Skills Training (CBSST) v. ACT, alone.


Options:
A: Arm Label: ACT + CBSST; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Social Skills Training (CBSST) | Arm Label: ACT only; Type: ACTIVE_COMPARATOR; Interventions: Other: Assertive Community Treatment (ACT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Social Skills Training (CBSST); Assigned to Arm(s): ACT + CBSST | Intervention Type: OTHER; Name: Assertive Community Treatment (ACT); Assigned to Arm(s): ACT only
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive enhancement therapy (CET) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Enriched supportive therapy (EST) | Intervention Type: BEHAVIORAL; Name: Cognitive enhancement therapy (CET); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enriched supportive therapy (EST); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Social Skills Training (CBSST), Behavioral: Social Skills Training, Behavioral: Goal Setting | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Goal-focused supportive contact (GFSC), Behavioral: Goal Setting | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Social Skills Training (CBSST); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Goal-focused supportive contact (GFSC); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Social Skills Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Goal Setting; Assigned to Arm(s): 1, 2
D: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center, Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule vs Colonoscopy in the Management of Recurrent Clostridium Difficile Infection (CDI)
Brief Summary: Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully. Endoscopic delivery requires significant health care utilization and associated cost. Therefore, it is extremely desirable if FMT can be infused by a non invasive modality, which would significantly reduce patient discomfort, procedure related risks and health care costs, while offering similar efficacy to colonoscopic delivery in the range of 90%.


Options:
A: Arm Label: FMT; Type: EXPERIMENTAL; Interventions: Other: Fecal microbiota transplantation | Arm Label: Fidaxomicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fidaxomicin | Arm Label: Vancomycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: OTHER; Name: Fecal microbiota transplantation; Assigned to Arm(s): FMT | Intervention Type: DRUG; Name: Fidaxomicin; Assigned to Arm(s): Fidaxomicin | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Vancomycin
B: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
C: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Biological: RBX2660 (microbiota suspension) | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Biological: RBX2660 (microbiota suspension), Other: Placebo | Intervention Type: BIOLOGICAL; Name: RBX2660 (microbiota suspension); Assigned to Arm(s): Group A, Group C | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group B, Group C
D: Arm Label: Delivery via capsule; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplant | Arm Label: Delivery via colonoscopy; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplant | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplant; Assigned to Arm(s): Delivery via capsule, Delivery via colonoscopy

Answer: D